Salesforce and Viz.ai announced a partnership that will embed Viz.ai’s AI‑driven disease‑detection and care‑coordination technology into Salesforce’s Agentforce Life Sciences platform, creating a real‑time clinical intelligence service for life‑science customers.
The integration will channel data from nearly 2,000 U.S. hospitals that serve 230 million lives into Agentforce, enabling guideline‑based next‑best actions across commercial, medical, and patient‑support teams. Mark Sullivan, President and Chief Revenue Officer for Salesforce’s Regulated Industries, said the collaboration “enables this transformation and creates a closed‑loop, agentic model.”
Strategically, the partnership expands Agentforce into a key growth area for Salesforce. In the most recent quarter, Salesforce reported $9.44 billion in revenue, up 8% year‑over‑year, with a non‑GAAP operating margin of 33.1%. Agentforce’s annual recurring revenue grew 330% year‑over‑year to more than $500 million, underscoring the platform’s rapid adoption. The deal also positions Salesforce to tap into the digital‑labor market, which is projected to reach $23.7 billion by 2034—significantly larger than the previously cited $12 trillion figure.
The partnership gives Salesforce a differentiated offering against competitors such as Microsoft Dynamics 365 and ServiceNow, by combining clinical and customer context to power AI‑driven workflow automation in regulated industries. The closed‑loop agentic workflows will help clinicians and patients receive timely, guideline‑based actions at the point of care, potentially accelerating Agentforce adoption in pharma and biotech.
Management notes that 94% of life‑sciences leaders expect AI agents to be critical for scaling organizational capacity, and the partnership is seen as a key step toward that goal. Analysts view the collaboration as a positive move that strengthens Salesforce’s AI momentum and expands its footprint in the life‑sciences vertical.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.